Videos
A Case of HR+ Metastatic Breast Cancer
JAK Inhibition for the Management of Primary Myelofibrosis
Primary Myelofibrosis
CLL Case Review: IgHV-Unmutated Therapy Options
David S. Hong, MD, discusses the potential for other TRK inhibitors in the treatment landscape for patients with thyroid cancer after the approval of larotrectinib.
Andre Goy, MD, discusses a few combinations that are being investigated for the treatment of patients with relapsed/refractory mantle cell lymphoma.
High-Risk IgVH-Unmutated Chronic Lymphocytic Leukemia
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Longitudinal Data Shapes Our Understanding of High-Risk Multiple Myeloma
2
Atezolizumab Elicits Durable Responses in R/R Extranodal NK/T-Cell Lymphoma
3
How the Immune System Drives Nerve Growth in TNBC
4
Intranasal NEO100 Meets Primary End Point in Recurrent IDH1-Mutant Glioma
5